IL1B and myocardial infarction: In a study supporting the mechanistic role ofIL-1β in the development of atherosclerotic thrombotic disease, a betterprognosis was found in patients receiving the anti-IL-1β monoclonalantibody canakinumab (CANTOS study) [25] compared to those on standard therapyand with previous myocardial infarction and evidence of active inflammation(elevated high-sensitivity C-reactive protein (hsCRP)), compounded with a betterprognosis.